The British Society of Gastroenterology (BSG) welcomes the findings of the latest round of the UK IBD Audit published today by the Royal College of Physicians, particularly noting the data on the use of biosimilar versions of infliximab in the NHS, and welcomes the contribution of BSG members to the findings.
In February this year the BSG has published a guidance document supporting their use in IBD patient care. The guidance advocates their use when prescribed by brand name, and emphasises the importance of ongoing pharmacovigilance for patients receiving these drugs through ongoing data collection through the UK IBD Registry.
With the NHS facing significant increasing financial pressures, biosimilars contribute towards improving IBD patient care and outcome while creating efficiency savings of up to £3million annually in this therapeutic area alone. We are encouraged by the reports key findings, including biosimilar versions of infliximab being shown to be as effective as other originator versions. It is vital that the reductions in costs to the NHS are used to reinvest in improvements to IBD services.
The BSG have worked hard with partners to develop a wider IBD programme in the UK – encompassing the IBD Audit, BSG’s IBD Registry and IBD Standards – and hope that this collaboration will continue to benefit patients with IBD.